


=> d l3
 L3 HAS NO ANSWERS
 L3 STR



VAR G1=O/N
 VAR G2=2/1/6/5
 NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 DEFAULT ELEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RSPEC 1
 NUMBER OF NODES IS 16

STEREO ATTRIBUTES: NONE

=> s l3 ful
 FULL SEARCH INITIATED 10:49:00 FILE 'REGISTRY'
 FULL SCREEN SEARCH COMPLETED - 68625 TO ITERATE

100.0% PROCESSED 68625 ITERATIONS 294 ANSWERS
 SEARCH TIME: 00.00.02

L5 294 SEA SSS FUL L3

=> fil caplus		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	157.10	157.31

FILE 'CAPLUS' ENTERED AT 10:49:08 ON 23 FEB 2004
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 23 Feb 2004 VOL 140 ISS 9
 FILE LAST UPDATED: 22 Feb 2004 (20040222/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l5


L6 14 L5
=> s 16 and py<2000
19722118 PY<2000
L7 2 L6 AND PY<2000

=>


=> d bib abs hitstr 1-2

L7 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1997:594631 CAPLUS
DN 127:262677
TI Methods of treating or preventing sleep apnea using di- and trisubstituted benzimidazoles
IN Gitter, Bruce D.; Iyengar, Smriti
PA Eli Lilly and Co., USA; Gitter, Bruce D.; Iyengar, Smriti
SO PCT Int. Appl., 117 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9731635	A1	19970904	WO 1997-US3113	19970226 <--
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	AU 9721390	A1	19970916	AU 1997-21390	19970226 <--
	US 6030992	A	20000229	US 1998-142026	19980827
PRAI	US 1996-12665P	P	19960301		
	WO 1997-US3113	W	19970226		
OS	MARPAT 127:262677				
GI					



I



II

AB This invention provides methods for the treatment or prevention of sleep apnea (no data) using substituted benzimidazoles I [R1, R2 = H, alkyl, alkoxy, (un)substituted heterocyclyl, phenylalkoxy, phenylalkylidenyl, heterocyclalkoxy, etc.; R3 = H, NO2, alkanoyl, alkyl, alkoxy, halo, (un)substituted amino, heterocyclyl, heterocyclalkoxy, hydroxyalkyl,


etc.; provided that both of R1 and R2 cannot be H) and their pharmaceutically acceptable salts or solvates. Examples include 174 syntheses of I, including both the preferred amine-containing target compds., and other compds. I serving primarily as intermediates. Eleven pharmaceutical formulations are also given. For instance, the intermediate compound I.HCl [R1 = 3,4,5-trimethoxyphenyl; R2 = CH2Ph; R3 = 6-OH] (prepared in 3 steps from 4-amino-3-nitrophenol) was etherified with 4-(2-chloroethyl)morpholine-HCl using K2CO3 in acetone to give a preferred title compound, II.

IT 196105-53-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug and/or intermediate; preparation of benzimidazoles for treatment or prevention of sleep apnea)

RN 196105-53-0 CAPLUS

CN Carbamic acid, butyl[2-(4-chlorophenyl)-1-phenyl-1H-benzimidazol-6-yl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)



L7 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1995:737335 CAPLUS

DN 123:143893

TI Preparation of benzimidazoles as prostacyclin PGI2 mimetics.

IN Kuhnke, Joachim; Eckle, Emil; Thierauch, Karl-Heinz; Verhallen, Peter

PA Schering A.-G., Germany

SO Ger. Offen., 10 pp.


CODEN: GWXXBX

DT Patent


LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 4330959	A1	19950316	DE 1993-4330959	19930909 <--
	WO 9507263	A1	19950316	WO 1994-EP2948	19940906 <--
	W: JP, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
PRAI	DE 1993-4330959		19930909		
OS	MARPAT 123:143893				
GI					



I




AB Title compds. [I; R1, R2 = (substituted) Ph, heteroaryl; R3, R4 = H, halo, alkyl, perfluoroalkyl, alkoxy, perfluoroalkoxy, carboxyl, alkoxycarbonyl, NO2, amino, etc.; A = bond; Q- or S-interrupted; alkylene, alkenylenes, alkynylene, Q1; n = 1-4; R5 = carboxyl, SO3H, PO3H2, tetrazolyl], were prepared as PGI2 mimetics and TXA2/PGH2 antagonists useful in treating thrombosis, arteriosclerosis, and hyperlipidemia (no data). Thus, 1,2-diphenyl-1H-benzimidazol-6-ol, MeO2CCH2Br, and K2CO3 were refluxed 3 h in acetone to give Me [(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]acetate, which was stirred 24 h in a mixture of aqueous NaOH, THF, and MeOH to give [(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]acetic acid.

IT 166396-70-9P 166396-71-0P 166396-72-1P
166396-73-2P 166396-74-3P 166396-75-4P
166396-76-5P 166396-77-6P 166396-78-7P
166396-79-8P 166396-80-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzimidazoles as prostacyclin PGI2 mimetics)


RN 166396-70-9 CAPLUS

CN Acetic acid, [(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]- (9CI) (CA INDEX NAME)




RN 166396-71-0 CAPLUS

CN Pentanoic acid, 5-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]- (9CI) (CA INDEX NAME)



RN 166396-72-1 CAPLUS


CN Butanoic acid, 4-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]- (9CI) (CA INDEX NAME)




RN 166396-73-2 CAPLUS

CN Pentanoic acid, 5-[[1-(4-nitrophenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]- (9CI) (CA INDEX NAME)


Does this read on it




RN 166396-74-3 CAPLUS
 CN Hexanoic acid, 6-[[1-(4-nitrophenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]-
 (9CI) (CA INDEX NAME)




RN 166396-75-4 CAPLUS
 CN Pentanoic acid, 5-[[1-[4-(acetamino)phenyl]-2-phenyl-1H-benzimidazol-6-yl]oxy]-
 (9CI) (CA INDEX NAME)




RN 166396-76-5 CAPLUS
 CN Pentanoic acid, 5-[[1-(3-nitrophenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]-
 (9CI) (CA INDEX NAME)




RN 166396-77-6 CAPLUS
 CN Hexanoic acid, 6-[[1-[3-(3-nitrophenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]-
 (9CI) (CA INDEX NAME)




RN 166396-78-7 CAPLUS
 CN Pentanoic acid, 5-[[1-[3-[[[4-(chlorophenyl)sulfonyl]amino]phenyl]-2-phenyl-1H-benzimidazol-6-yl]oxy]-
 (9CI) (CA INDEX NAME)



RN 166396-79-8 CAPLUS
 CN Pentanoic acid, 5-[[1-[3-(acetylamino)phenyl]-2-phenyl-1H-benzimidazol-6-yl]oxy]- (9CI) (CA INDEX NAME)




RN 166396-80-1 CAPLUS
 CN Pentanoic acid, 5-[[1-[4-[[[(4-chlorophenyl)sulfonyl]amino]phenyl]-2-phenyl-1H-benzimidazol-6-yl]oxy]- (9CI) (CA INDEX NAME)




IT 166396-81-2P 166396-82-3P 166396-83-4P
 166396-84-5P 166396-85-6P 166396-86-7P
 166396-87-8P 166396-90-3P 166396-91-4P
 166396-92-5P 166396-93-6P 166396-94-7P
 166396-95-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of benzimidazoles as prostacyclin PGI2 mimetics)


RN 166396-81-2 CAPLUS
 CN Acetic acid, [(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 166396-82-3 CAPLUS
 CN Pentanoic acid, 5-[[1,2-diphenyl-1H-benzimidazol-6-yl]oxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 166396-83-4 CAPLUS
 CN Butanoic acid, 4-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 166396-84-5 CAPLUS
 CN Pentanoic acid, 5-[[1-(4-nitrophenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 166396-85-6 CAPLUS
 CN Hexanoic acid, 6-[[1-(4-nitrophenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 166396-86-7 CAPLUS
 CN Pentanoic acid, 5-[[1-(4-aminophenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)




RN 166396-87-8 CAPLUS
 CN Pentanoic acid, 5-[[1-[4-(acetylamino)phenyl]-2-phenyl-1H-benzimidazol-6-yl]oxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 166396-90-3 CAPLUS
 CN Pentanoic acid, 5-[[1-(3-nitrophenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 166396-91-4 CAPLUS
 CN Hexanoic acid, 6-[[1-(3-nitrophenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 166396-92-5 CAPLUS
 CN Pentanoic acid, 5-[[1-(3-aminophenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 166396-93-6 CAPLUS
 CN Pentanoic acid, 5-[[1-[3-[[4-(4-chlorophenyl)sulfonyl]amino]phenyl]-2-phenyl-1H-benzimidazol-6-yl]oxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 166396-94-7 CAPLUS
 CN Pentanoic acid, 5-[[1-[3-(acetylamino)phenyl]-2-phenyl-1H-benzimidazol-6-yl]oxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 166396-95-8 CAPLUS
 CN Pentanoic acid, 5-[[1-[4-[[4-(4-chlorophenyl)sulfonyl]amino]phenyl]-2-phenyl-1H-benzimidazol-6-yl]oxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 166396-71-0 CAPLUS
 CN Pentanoic acid, 5-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]- (9CI) (CA INDEX NAME)




RN 166396-72-1 CAPLUS
 CN Butanoic acid, 4-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]- (9CI) (CA INDEX NAME)




RN 166396-73-2 CAPLUS
 CN Pentanoic acid, 5-[[1-(4-nitrophenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]- (9CI) (CA INDEX NAME)




RN 166396-74-3 CAPLUS
 CN Hexanoic acid, 6-[[1-(4-nitrophenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]- (9CI) (CA INDEX NAME)




RN 166396-75-4 CAPLUS
 CN Pentanoic acid, 5-[[1-[4-(acetylamino)phenyl]-2-phenyl-1H-benzimidazol-6-yl]oxy]- (9CI) (CA INDEX NAME)




RN 166396-82-3 CAPLUS
 CN Pentanoic acid, 5-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]-, methyl ester
 (9CI) (CA INDEX NAME)




RN 166396-83-4 CAPLUS
 CN Butanoic acid, 4-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]-, ethyl ester
 (9CI) (CA INDEX NAME)




RN 166396-84-5 CAPLUS
 CN Pentanoic acid, 5-[[1-(4-nitrophenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 166396-85-6 CAPLUS
 CN Hexanoic acid, 6-[[1-(4-nitrophenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]-, methyl ester (9CI) (CA INDEX NAME)




166396-78-7 CAPLUS
 CN Pentanoic acid, 5-[[1-[3-[[4-(4-chlorophenyl)sulfonyl]amino]phenyl]-2-phenyl-1H-benzimidazol-6-yl]oxy]- (9CI) (CA INDEX NAME)



RN 166396-79-8 CAPLUS
 CN Pentanoic acid, 5-[[1-[3-(acetylamino)phenyl]-2-phenyl-1H-benzimidazol-6-yl]oxy]- (9CI) (CA INDEX NAME)



RN 166396-80-1 CAPLUS
 CN Pentanoic acid, 5-[[1-[4-[[4-(4-chlorophenyl)sulfonyl]amino]phenyl]-2-phenyl-1H-benzimidazol-6-yl]oxy]- (9CI) (CA INDEX NAME)



IT 166396-81-2P 166396-82-3P 166396-83-4P
 166396-84-5P 166396-85-6P 166396-86-7P
 166396-87-8P 166396-90-3P 166396-91-4P
 166396-92-5P 166396-93-6P 166396-94-7P
 166396-95-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of benzimidazoles as prostacyclin PGI2 mimetics)

RN 166396-81-2 CAPLUS
 CN Acetic acid, [(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]-, methyl ester (9CI) (CA INDEX NAME)

